ArticleBMJ open2024

Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study.

Keiko Imamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.